The CoviVac vaccine against COVID-19, developed by Russia's Chumakov research institute, was proven safe and efficient in the clinical trials, health minister Mikhail Murashko said on Saturday
MOSCOW (Pakistan Point News / Sputnik - 20th February, 2021) The CoviVac vaccine against COVID-19, developed by Russia's Chumakov research institute, was proven safe and efficient in the clinical trials, health minister Mikhail Murashko said on Saturday.
Earlier in the day, Russian Prime Minister Mikhail Mishustin announced that the country had registered its third vaccine against the coronavirus. The head of the Chumakov institute announced plans to promote the vaccine to foreign markets.
"Russia's health ministry has made a decision to register the third Russian vaccine to prevent the coronavirus � CoviVac, developed by the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products. Clinical trials with participation of volunteers confirmed vaccine safety and efficiency," Murashko told reporters.
Phase 3 clinical trials are scheduled for March and will involve 3,000 participants, Russia's ministry of science said.
According to the ministry, the CoviVac vaccine is currently recommended for people aged between 18 and 60, with an expansion possible following phase 2 trials.
